blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2830631

EP2830631 - ADMINISTRATION OF ERITORAN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT ORTHOMYXOVIRUS INFECTIONS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  28.09.2018
Database last updated on 05.10.2024
FormerThe patent has been granted
Status updated on  20.10.2017
FormerGrant of patent is intended
Status updated on  13.10.2017
FormerExamination is in progress
Status updated on  22.09.2017
FormerGrant of patent is intended
Status updated on  17.05.2017
FormerExamination is in progress
Status updated on  04.11.2016
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL, IS		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
University of Maryland, Baltimore
Office of Technology Transfer
620 W.Lexington Street, 4th Floor
Baltimore MD 21201 / US
[2015/06]
Inventor(s)01 / VOGEL, Stefanie
10061 Cape Ann Drive
Columbia, Maryland 21046 / US
02 / SHIREY, Kari Ann
4 Cedar Tree Court Apt. A
Cockeysville, Maryland 21030 / US
 [2015/06]
Representative(s)Regimbeau
20, rue de Chazelles
75847 Paris Cedex 17 / FR
[2015/06]
Application number, filing date13708644.304.03.2013
[2017/47]
WO2013US28856
Priority number, dateUS201261616784P28.03.2012         Original published format: US 201261616784 P
US201361771339P01.03.2013         Original published format: US 201361771339 P
[2015/06]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013148072
Date:03.10.2013
Language:EN
[2013/40]
Type: A1 Application with search report 
No.:EP2830631
Date:04.02.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 03.10.2013 takes the place of the publication of the European patent application.
[2015/06]
Type: B1 Patent specification 
No.:EP2830631
Date:22.11.2017
Language:EN
[2017/47]
Search report(s)International search report - published on:EP03.10.2013
ClassificationIPC:A61K31/7024, A61K45/06, A61P31/16
[2015/06]
CPC:
A61K31/7024 (EP,CN,US); A61K45/06 (EP,CN,US); A61P31/16 (EP);
A61P43/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/06]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERABREICHUNG VON ERITORAN ODER PHARMAZEUTISCH AKZEPTABLEN SALZEN DAVON ZUR BEHANDLUNG VON ORTHOMYXOVIRUSINFEKTIONEN[2015/06]
English:ADMINISTRATION OF ERITORAN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT ORTHOMYXOVIRUS INFECTIONS[2015/06]
French:ADMINISTRATION D'ERITORAN OU DES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI POUR TRAITER DES INFECTIONS À ORTHOMYXOVIRUS[2015/06]
Entry into regional phase08.10.2014National basic fee paid 
08.10.2014Designation fee(s) paid 
08.10.2014Examination fee paid 
Examination procedure08.10.2014Examination requested  [2015/06]
15.07.2015Amendment by applicant (claims and/or description)
28.06.2016Despatch of a communication from the examining division (Time limit: M04)
04.11.2016Reply to a communication from the examining division
18.05.2017Communication of intention to grant the patent
15.09.2017Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
15.09.2017Fee for grant paid
15.09.2017Fee for publishing/printing paid
13.10.2017Information about intention to grant a patent
13.10.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  28.06.2016
Opposition(s)23.08.2018No opposition filed within time limit [2018/44]
Fees paidRenewal fee
10.03.2015Renewal fee patent year 03
31.03.2016Renewal fee patent year 04
27.03.2017Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU04.03.2013
AL22.11.2017
AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
MK22.11.2017
PL22.11.2017
PT22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
TR22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
IE04.03.2018
LU04.03.2018
MT04.03.2018
IS22.03.2018
BE31.03.2018
[2020/33]
Former [2020/31]HU04.03.2013
AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
MK22.11.2017
PL22.11.2017
PT22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
TR22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
IE04.03.2018
LU04.03.2018
MT04.03.2018
BE31.03.2018
Former [2020/28]HU04.03.2013
AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
PL22.11.2017
PT22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
TR22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
IE04.03.2018
LU04.03.2018
MT04.03.2018
BE31.03.2018
Former [2020/16]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
PL22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
TR22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
IE04.03.2018
LU04.03.2018
MT04.03.2018
BE31.03.2018
Former [2020/08]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
PL22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
IE04.03.2018
LU04.03.2018
MT04.03.2018
BE31.03.2018
Former [2019/12]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
PL22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
IE04.03.2018
LU04.03.2018
BE31.03.2018
Former [2019/09]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
PL22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
IE04.03.2018
LU04.03.2018
Former [2019/04]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
PL22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
LU04.03.2018
Former [2018/52]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
PL22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/40]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
PL22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/39]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
PL22.11.2017
RS22.11.2017
SE22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/37]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
PL22.11.2017
RS22.11.2017
SE22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/35]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
RS22.11.2017
SE22.11.2017
SK22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/24]AT22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
RS22.11.2017
SE22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/22]ES22.11.2017
FI22.11.2017
LT22.11.2017
NO22.02.2018
Cited inInternational search[A]US2007072824  (KAWANO TETSU [JP], et al) [A] 1-37* the whole document *;
 [I]US2010015125  (CRISPE IAN NICHOLAS [US], et al) [I] 1,3-14,16-26,28-37 * paragraphs [0037] , [0118] , [ 0120] *
by applicantUS5681824
 US6906042
 US2008227991
    - NHU ET AL., MUCOSAL IMMUNOLOGY, (2010), vol. 3, no. 1, pages 29 - 39
    - Y. IMAI ET AL., CELL, (2008), vol. 133, pages 235 - 249
    - J. PHARMACEUTICAL SCIENCES, (1977), vol. 66, pages 1 - 19
    - J.R. TEJARO ET AL., J. IMMUNOL., (2009), vol. 182, pages 634 - 6843
    - OTTOLINI, J. GEN. VIROL., (2005), vol. 86, pages 2523 - 2830
    - M.D. TATE, RESPIRATORY RESEARCH, (20071209), vol. 57, pages 1 - 13
    - SHIREY KA ET AL., J. LEUKOC. BIOL., (2011), vol. 89, no. 3, pages 351 - 7
    - SHIREY KA ET AL., J. IMMUNOL., (2008), vol. 181, no. 6, pages 4159 - 67
    - SHIREY KA ET AL., MUCOSAL IMMUNOLOGY, (2010), vol. 3, no. 3, pages 291 - 300
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.